Comparative preclinical evaluation of a microtubule PET tracer with a beta‐amyloid PET tracer in AD mice

Abstract Background Currently available PET tracers used in Alzheimer's disease (AD) have limited utility prognosis and revealing reliable clinicopathologic correlations of disease. Therefore, identification validation novel biomarkers for AD progression preclinical onset through noninvasive neuroimaging is a top priority biomedical research. We proposed to target microtubules (MTs) as an imaging preclinical, postmortem clinical studies that support the implication altered regulation MTs positively correlated with neurodegeneration process. Furthermore, MT loss contributed large number mutated proteins, enzymes, post‐translational modifications compared other targets. targeting brain may be advantageous, cumulative final common pathway variety biochemical pathologies leading AD. [ 11 C]MPC‐6827 pioneer BBB‐penetrating tracer vivo brain. 1,2 Herein, we report comparative binding C]MPC‐6827, C]PiB Aβ over expressing APP transgenic J20 mice controls. Method were synthesized using GE Tracerlab FX2 MEI FX2N modules. Dynamic scans performed 30 min after tail vein injection 6‐month‐old littermates (n=4) Siemens Focus 220 microPET scanner. Image analyses Mango software on reconstructed data. Result image show ∼30% reduced whole uptake whereas, exhibited modest higher (∼10%) than control mice. Standardized values (SUVs) similar trend prefrontal cortex (PFC) hippocampus Conclusion Our preliminary mice, brain, PFC inversely binding. The effect size seems C]PiB. could human NDs. Acknowledgement: This work was funded by Center Biomedical Neuroscience (CBN) 2020‐2021, UT Health San Antonio, Texas, USA.